Lakefront Biotherapeutics NV Free Cash Flow (FCF) History (LKFT)
Lakefront Biotherapeutics NV reported −€271.2M in free cash flow for fiscal 2025, an increase of €65.6M from the previous fiscal year, with a free cash flow margin of −24.38%.
View full Lakefront Biotherapeutics NV company overviewLakefront Biotherapeutics NV free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | −€271.2M | €65.6M | — | −24.38% |
| 2024 | 2024-12-31 | −€336.7M | €87.9M | — | −122.16% |
| 2023 | 2023-12-31 | −€424.7M | €103.3M | — | −177.15% |
| 2022 | 2022-12-31 | −€527.9M | €30.1M | — | −218.83% |
| 2021 | 2021-12-31 | −€558.0M | −€88.2M | — | −238.08% |
| 2020 | 2020-12-31 | −€469.9M | −€3.66B | — | −98.29% |
| 2019 | 2019-12-31 | €3.19B | €3.34B | — | +381.63% |
| 2018 | 2018-12-31 | −€152.9M | −€516,000 | — | −54.85% |
| 2017 | 2017-12-31 | −€152.3M | −€387.3M | — | −119.87% |
| 2016 | 2016-12-31 | €234.9M | €355.6M | — | +181.40% |
| 2015 | 2015-12-31 | −€120.7M | — | — | −305.06% |
Lakefront Biotherapeutics NV quarterly free cash flow
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|
Lakefront Biotherapeutics NV free cash flow growth trends
Over the last five reported fiscal years, free cash flow grew from −€469.9M to −€271.2M, a net increase of €198.7M.
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Lakefront Biotherapeutics NV filings at SEC.gov ↗